Biomedicine is one of the three leading industries in Shanghai, and the industrial scale is expected to exceed 700 billion yuan in 2021, which is a new level of industrial scale after reaching 600 billion yuan for the first time in 2020. On January 21, the Municipal Commission of Economy and Information Technology announced ten major events in Shanghai's biomedical industry in 2021.
The first is to deeply implement the "Zhangjiang R&D + Made in Shanghai" action to accelerate the landing of innovative achievements in Shanghai. In order to solve the pain points of Zhangjiang biomedical enterprises "blossoming inside the wall and outside the wall", Shanghai issued the "Several Measures on Promoting the Coordinated Development of Biomedical R&D and Manufacturing in Shanghai", accelerating the linkage of industrial space, and the local transformation trend of Zhangjiang's innovative achievements is obvious, and more than 50 projects with the attributes of "Zhangjiang R&D + Made in Shanghai" such as Minimally Invasive Medical, Heyuan Biology and Jiahe Biology have landed, with a total investment of about 50 billion yuan.
Second, two new cell therapy drugs were approved for marketing. On June 22 and September 1, 2021, two CAR-T cell therapy (chimeric antigen receptor T cell immunotherapy) products, namely Fosun Kate Biotechnology Co., Ltd. Agironse Injection, and Shanghai WuXi Junuo Biotechnology Co., Ltd. Reiki Olense Injection, successively obtained the Drug Registration Certificate of the State Drug Administration, becoming the only two listed cell therapy products in mainland China.
The third is to help the global fight against the epidemic, and the prevention and control of the new crown urgently needs a comprehensive breakthrough in the development of pharmaceutical equipment. Among them, the Shanghai Pharmaceutical Cansino new crown vaccine production base project and the Shanghai Institute of Biological Products New Crown Vaccine Packaging Project started construction in February and May 2021 respectively, both of which achieved the construction of the year and put into production in the same year, creating the speed of biomedical engineering construction in Shanghai.
The fourth is to build a "R&D + clinical + manufacturing + application" industrial chain policy support system, and a new round of industrial high-quality development opinions are released. In May 2021, the Shanghai Municipal Government issued the Several Opinions on Promoting the High-quality Development of the Biomedical Industry in Shanghai, which provided layout and policy support for the development of the biomedical industry in Shanghai in the next three years.
The fifth is to build a highland of innovation in the biomedical industry in Zhangjiang, and the first local industrial legislation has been introduced. According to the requirements of "bold trial, bold breakthrough and independent reform", Shanghai has tailored the biomedical industry development regulations for Pudong New Area.
Sixth, the "14th Five-Year Plan" for the development of the biomedical industry was promulgated, clarifying the coordinated development direction of the six chains of the future industry. The six chains refer to industry, space, innovation, service, talent, and policy collaboration.
Seventh, the first International Biomedical Industry Week has opened with great attention and created world-class brand activities. From October 11 to 14, 2021, the first Shanghai International Biomedical Industry Week was successfully held, becoming the world's largest life and health conference since the outbreak of the new crown epidemic, bringing together more than 100 top scientists, more than 100 top investors, and more than 1,000 top entrepreneurs, introducing heavyweight international brand conferences such as JPMorgan Chase and DIA (Society for Drug Information). During the Industry Week, a total of 86 projects were signed and landed, with a total investment of 61.3 billion yuan.
Eighth, the scale of the industry continues to step up to a new level, and innovative pharmaceutical devices and market players are vigorously developing. In 2021, Shanghai will add 8 new approved domestic innovative drugs of a class, a new high in the calendar year; 12 new products will enter the special approval channel of national innovative medical devices, accounting for one-fifth of the country. In 2021, 6 biomedical enterprises such as Zhijiang Biologics and Haoyuan Pharmaceutical landed on the Science and Technology Innovation Board.
The ninth is the establishment of the Yangtze River Delta Pharmaceutical Innovation and Development Alliance and the first batch of biomedical product registration guidance service workstations.
Tenth, the acceleration of clinical trial accelerators has increased significantly, and high-quality clinical resources have become a new driving force for industrial development. In 2021, 43 clinical trials entered the Clinical Trial Accelerator, containing 26 drugs and 17 device varieties, covering 6 specialties and more than 20 indications.
It is also reported that the Shanghai International Biomedical Industry Week, which is one of the ten major events, will continue to be launched this year, but will run through the whole year in the form of "5+360". Among them, the "5-day industry week" is scheduled to be held from September 26 to 30 this year, and the "360-day activity" will continue to be created, and the "Biomedical Week National Tour" and a series of forum activities focusing on Shanghai will be carried out nationwide. At present, 6 units, including JPMorgan Chase, Fosun Pharma, Shanghai Pharmaceutical, Zhangjiang Group, DIA Pharmaceutical Information Society and E Fangda, have signed contracts as the first batch of strategic partners of Shanghai International Biomedical Industry Week in 2022.
Column Editor-in-Chief: Li Ye Text Editor: Li Ye
Source: Author: Li Ye